Amended Claims

1. **(currently amended)** A pharmaceutical composition**, wherein the composition:** ~~**comprising**~~

comprises a polytartrate polymer and at least one pharmaceutically active material**,** ~~**characterised in that the composition**~~

is capable of releasing the pharmaceutically active material in a pulsatile manner **when the composition is administered to a human or other animal,** and

is **in the form of a** ~~**obtainable by forming the**~~ tablet **prepared** with a **tablet press using a** compression force ~~**between**~~ **of from** 10 **to** **[[and]]** 65 kN/cm^2.

2. **(currently amended)** The composition according to claim 1**, wherein the compression force in the tablet press** ~~**characterised in that the composition**~~ is ~~**at a compression force between**~~ **from** 20 **to** **[[and]]** 50 kN/cm^2.

3. **(currently amended)** The composition according to claim 1**, wherein** ~~**characterised in that**~~ the polytartrate polymer forms degradation products that increase the pressure inside the composition **when the composition is administered to a human or other animal**.

4. **(currently amended)** The composition according to claim 3**, wherein the degradation products comprise at least one compound selected from the group consisting of** ~~**characterised in that the polytartrate polymer forms during degradation**~~ a C1 to C4 alcohol, aldehyde**,** **[[or]]** ester**, and** **[[or]]** acetone.

5. **(currently amended)** The composition according to claim 4**, wherein the degradation products comprise at least one compound selected from the group consisting of** ~~**characterised that the polytartrate polymer forms during degradation**~~ methanol, ethanol, propanol, isopropanol**, and** **[[or]]** acetone.

6. **(currently amended)** The composition according to claim 1, **wherein** ~~**characterised in that**~~ the polytartrate polymer is **a polycondensate** ~~**selected from the group of polycondensates**~~ of**:**

dimethyl tartrate**;** ~~**[[,]]**~~ diethyl tartrate**;** ~~**[[,]]**~~ diisopropyl tartrate**;** or **one or more** copolymers **of at least two of dimethyl tartrate, diethyl tartrate, and diisopropyl tartrate;** ~~**thereof**~~ and

one or more 2,3-O-alkylidenetartaric acid derivatives.

7. **(currently amended)** The composition according to claim 6, **wherein** ~~**characterised in that**~~ the polytartrate polymer is 2'3'-(1',4'-diethyl)-L-tartryl poly-(2,3-O-isopropylidene)-L-tartrate.

8. **(currently amended)** The composition according to the claim 1, **wherein** ~~**characterised in that**~~ the polytartrate polymer has a glass transition temperature that is greater than 40°C.

9. **(currently amended)** The composition according to claim 1, **wherein** ~~**characterised in that**~~ the pharmaceutically active material **comprises at least one material** ~~**[[is]]**~~ selected from **the group consisting** ~~**one or more**~~ of antigens, antibodies**,** **and** ~~**[[or]]**~~ pharmaceutical substances.

10. **(currently amended)** The composition according to claim 9, **wherein** ~~**characterised in that**~~ the pharmaceutically active material is a GnRH agonist.

11. **(currently amended)** The composition according to claim 10, **wherein** ~~**characterised in that**~~ the pharmaceutically active material is buserelin.

12. **(currently amended)** The composition according to claim ~~**[[11]]**~~ **10, wherein** ~~**characterised in that**~~ the pharmaceutically active material is azagly nafarelin.

13. **(currently amended)** The composition according to claim 1**, wherein** ~~**characterised in that**~~ the composition additionally comprises one or more **[[of]]** pharmaceutically acceptable excipients or adjuvants.

14. **(currently amended)** **A process** ~~**Process**~~ for **preparing** ~~**the preparation of**~~ a polytartrate composition according to claim 1**, wherein the process comprises:** ~~**involving the steps of**~~

a) mixing an effective amount of a pharmaceutically active material with **a** **[[the]]** polytartrate polymer**, and**

b) shaping the mixture **with** **[[by a]]** tabletting equipment to form compressed tablets by applying a compression force **of from** ~~**between**~~ 10 **to** **[[and]]** 65 kN/cm^2.

15. **(currently amended)** **The process** according to claim 14**, wherein** ~~**characterised in that**~~ the pharmaceutically active material and the polytartrate polymer are mixed in a powdered form.

16. **(currently amended)** The process according to claim 14**, wherein** ~~**characterised in that**~~ the mixture is sieved ~~**and optionally additional tabletting excipients are added to the mixture**~~.

17. **(currently amended)** A method of administering a pulsatile pharmaceutically active material to a **[[body]]** **human or other animal, wherein the method comprises** ~~**comprising the step of**~~ administering the composition of Claim 1 to the **[[body]]** **human or other animal**.

18. **(currently amended)** The method of Claim 17**,** wherein the **method comprises administering the composition of Claim 1 to** ~~**body is selected from an animal body and**~~ a human ~~**body**~~.

19. **(currently amended)** A method of administering a pharmaceutically active material to a **human or other animal, wherein:**

the method comprises ~~**body comprising the steps of:**~~ administering a composition of Claim 1 to the **human or other animal, and** ~~**body wherein**~~

a majority of the pharmaceutically **active material** is released in ~~**at least two phases comprising**~~ an initial burst and a second burst.

Claim 20 (canceled).

21. **(new)** The method of Claim 17, wherein the method comprises administering the composition of Claim 1 to a non-human animal.